Posttraumatic stress disorder in people who use drugs: syringe services program utilization, treatment need, and preferences for onsite mental health care.
Humans
Stress Disorders, Post-Traumatic
/ epidemiology
Male
Female
Adult
Needle-Exchange Programs
/ statistics & numerical data
New York City
/ epidemiology
Middle Aged
Mental Health Services
/ statistics & numerical data
Opioid-Related Disorders
/ epidemiology
Substance Abuse, Intravenous
/ epidemiology
Patient Preference
Health Services Needs and Demand
/ statistics & numerical data
Prevalence
Health Services Accessibility
/ statistics & numerical data
Patient Acceptance of Health Care
/ statistics & numerical data
Harm reduction
Integrated posttraumatic stress disorder and substance use disorder care
Opioid-related overdose
Psychiatric comorbidity
Substance use disorders
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
01 Jun 2024
01 Jun 2024
Historique:
received:
23
05
2023
accepted:
09
05
2024
medline:
2
6
2024
pubmed:
2
6
2024
entrez:
2
6
2024
Statut:
epublish
Résumé
Syringe services programs (SSPs) are critical healthcare access points for people with opioid use disorder (OUD) who face treatment utilization barriers. Co-locating care for common psychiatric comorbidities, like posttraumatic stress disorder (PTSD), at SSPs may reduce harms and enhance the health of individuals with OUD. To guide the development of onsite psychiatric care at SSPs, we collected quantitative survey data on the prevalence of PTSD, drug use patterns, treatment experiences associated with a probable PTSD diagnosis, and attitudes regarding onsite PTSD care in a convenience sample of registered SSP clients in New York City. Study participants were administered the PTSD Checklist for the DSM-5 (PCL-5) and asked about sociodemographic characteristics, current drug use, OUD and PTSD treatment histories, and desire for future SSP services using a structured interview. Probable PTSD diagnosis was defined as a PCL-5 score ≥ 31. Of the 139 participants surveyed, 138 experienced at least one potentially traumatic event and were included in the present analysis. The sample was primarily male (n = 108, 78.3%), of Hispanic or Latinx ethnicity (n = 76, 55.1%), and middle-aged (M = 45.0 years, SD = 10.6). The mean PCL-5 score was 35.2 (SD = 21.0) and 79 participants (57.2%) had a probable PTSD diagnosis. We documented frequent SSP utilization, significant unmet PTSD treatment need, and high interest in onsite PTSD treatment. Study findings point to the ubiquity of PTSD in people with OUD who visit SSPs, large gaps in PTSD care, and the potential for harm reduction settings like SSPs to reach people underserved by the healthcare system who have co-occurring OUD and PTSD.
Sections du résumé
BACKGROUND
BACKGROUND
Syringe services programs (SSPs) are critical healthcare access points for people with opioid use disorder (OUD) who face treatment utilization barriers. Co-locating care for common psychiatric comorbidities, like posttraumatic stress disorder (PTSD), at SSPs may reduce harms and enhance the health of individuals with OUD. To guide the development of onsite psychiatric care at SSPs, we collected quantitative survey data on the prevalence of PTSD, drug use patterns, treatment experiences associated with a probable PTSD diagnosis, and attitudes regarding onsite PTSD care in a convenience sample of registered SSP clients in New York City.
METHODS
METHODS
Study participants were administered the PTSD Checklist for the DSM-5 (PCL-5) and asked about sociodemographic characteristics, current drug use, OUD and PTSD treatment histories, and desire for future SSP services using a structured interview. Probable PTSD diagnosis was defined as a PCL-5 score ≥ 31.
RESULTS
RESULTS
Of the 139 participants surveyed, 138 experienced at least one potentially traumatic event and were included in the present analysis. The sample was primarily male (n = 108, 78.3%), of Hispanic or Latinx ethnicity (n = 76, 55.1%), and middle-aged (M = 45.0 years, SD = 10.6). The mean PCL-5 score was 35.2 (SD = 21.0) and 79 participants (57.2%) had a probable PTSD diagnosis. We documented frequent SSP utilization, significant unmet PTSD treatment need, and high interest in onsite PTSD treatment.
CONCLUSIONS
CONCLUSIONS
Study findings point to the ubiquity of PTSD in people with OUD who visit SSPs, large gaps in PTSD care, and the potential for harm reduction settings like SSPs to reach people underserved by the healthcare system who have co-occurring OUD and PTSD.
Identifiants
pubmed: 38824597
doi: 10.1186/s12954-024-01019-5
pii: 10.1186/s12954-024-01019-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108Subventions
Organisme : NIDA NIH HHS
ID : R01DA0448780
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
doi: 10.1176/appi.books.9780890425596
Goytan A, Lee W, Dong H, Hayashi K, Milloy MJ, Kerr T. The impact of PSTD on service access among people who use drugs in Vancouver, Canada. Subst Abuse Treat Prev Policy. 2021;16(1):53.
pubmed: 34174927
pmcid: 8233608
doi: 10.1186/s13011-021-00390-x
Kidorf M, Solazzo S, Yan H, Brooner RK. Psychiatric and substance use comorbidity in treatment-seeking injection opioid users referred from syringe exchange. J Dual Diagnosis. 2018;14(4):193–200.
doi: 10.1080/15504263.2018.1510148
Lee WK, Hayashi K, DeBeck K, Milloy MJS, Grant C, Wood E, et al. Association between posttraumatic stress disorder and nonfatal drug overdose. Psychol Trauma: Theory Res Pract Policy. 2020;12(4):373–80.
doi: 10.1037/tra0000511
Mitra S, Lee W, Hayashi K, Boyd J, Milloy MJ, Dong H, et al. A gender comparative analysis of post-traumatic stress disorder among a community-based cohort of people who use drugs in Vancouver, Canada. Addict Behav. 2021;115:106793.
pubmed: 33421746
pmcid: 7971763
doi: 10.1016/j.addbeh.2020.106793
Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy. 2009;20(3):193–201.
pubmed: 19147339
doi: 10.1016/j.drugpo.2008.10.003
Forbes D, Lockwood E, Phelps A, Wade D, Creamer M, Bryant RA, et al. Trauma at the hands of another: distinguishing PTSD patterns following intimate and nonintimate interpersonal and noninterpersonal trauma in a nationally representative sample. J Clin Psychiatry. 2013;74(2):21205.
doi: 10.4088/JCP.13m08374
Plotzker RE, Metzger DS, Holmes WC. Childhood sexual and physical abuse histories, PTSD, depression, and HIV risk outcomes in women injection drug users: a potential mediating pathway. Am J Addictions. 2007;16(6):431–8.
doi: 10.1080/10550490701643161
Mills KL, Lynskey M, Teesson M, Ross J, Darke S. Post-traumatic stress disorder among people with heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence and correlates. Drug Alcohol Depend. 2005;77(3):243–9.
doi: 10.1016/j.drugalcdep.2004.08.016
pubmed: 15734224
Ecker AH, Hundt N. Posttraumatic stress disorder in opioid agonist therapy: a review. Psychol Trauma. 2017.
Mills KL, Teesson M, Ross J, Darke S. The impact of post-traumatic stress disorder on treatment outcomes for heroin dependence. Addiction. 2007;102(3):447–54.
pubmed: 17298653
doi: 10.1111/j.1360-0443.2006.01711.x
Kidorf M, King VL, Pierce J, Kolodner K, Brooner RK. Benefits of concurrent syringe exchange and substance abuse treatment participation. J Subst Abuse Treat. 2011;40(3):265–71.
pubmed: 21255959
pmcid: 3056913
doi: 10.1016/j.jsat.2010.11.011
Peirce JM, Brooner RK, King VL, Kidorf MS. Effect of traumatic event reexposure and PTSD on substance use disorder treatment response. Drug Alcohol Depend. 2016;158:126–31.
pubmed: 26652898
doi: 10.1016/j.drugalcdep.2015.11.006
King VL, Brooner RK, Peirce J, Kolodner K, Kidorf M. Challenges and outcomes of parallel care for patients with co-occurring psychiatric disorder in methadone maintenance treatment. J Dual Diagnosis. 2014;10(2):60–7.
doi: 10.1080/15504263.2014.906132
Killeen TK, Back SE, Brady KT. Implementation of integrated therapies for comorbid post-traumatic stress disorder and substance use disorders in community substance abuse treatment programs. Drug Alcohol Rev. 2015;34(3):234–41.
pubmed: 25737377
pmcid: 4737595
doi: 10.1111/dar.12229
Muncan B, Walters SM, Ezell J, Ompad DC. They look at us like junkies: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct J. 2020;17(1):53.
pubmed: 32736624
pmcid: 7393740
doi: 10.1186/s12954-020-00399-8
Fong C, Mateu-Gelabert P, Ciervo C, Eckhardt B, Aponte-Melendez Y, Kapadia S, et al. Medical provider stigma experienced by people who use drugs (MPS-PWUD): development and validation of a scale among people who currently inject drugs in New York City. Drug Alcohol Depend. 2021;221:108589.
pubmed: 33621804
pmcid: 8029599
doi: 10.1016/j.drugalcdep.2021.108589
Hien DA, Morgan-López AA, Saavedra LM, Ruglass LM, Ye A, López-Castro T, et al. Project Harmony: a meta-analysis with individual patient data on behavioral and pharmacologic trials for comorbid posttraumatic stress and alcohol or other drug use disorders. AJP. 2023;180(2):155–66.
doi: 10.1176/appi.ajp.22010071
pubmed: 36475373
Paquette CE, Syvertsen JL, Pollini RA. Stigma at every turn: health services experiences among people who inject drugs. Int J Drug Policy. 2018;57:104–10.
pubmed: 29715589
pmcid: 5994194
doi: 10.1016/j.drugpo.2018.04.004
Wang L, Panagiotoglou D, Min JE, DeBeck K, Milloy MJ, Kerr T, et al. Inability to access health and social services associated with mental health among people who inject drugs in a Canadian setting. Drug Alcohol Depend. 2016;168:22–9.
pubmed: 27610937
pmcid: 5086265
doi: 10.1016/j.drugalcdep.2016.08.631
Biancarelli DL, Biello KB, Childs E, Drainoni M, Salhaney P, Edeza A, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019;198:80–6.
pubmed: 30884432
pmcid: 6521691
doi: 10.1016/j.drugalcdep.2019.01.037
Lago RR, Peter E, Bógus CM. Harm reduction and tensions in trust and distrust in a mental health service: a qualitative approach. Subst Abuse Treat Prev Policy. 2017;12(1):12.
doi: 10.1186/s13011-017-0098-1
pubmed: 28270218
pmcid: 5341417
Macneil J, Pauly B. Needle exchange as a safe haven in an unsafe world. Drug Alcohol Rev. 2011;30(1):26–32.
pubmed: 21219494
doi: 10.1111/j.1465-3362.2010.00188.x
Treloar C, Rance J, Yates K, Mao L. Trust and people who inject drugs: the perspectives of clients and staff of Needle Syringe Programs. Int J Drug Policy. 2016;27:138–45.
doi: 10.1016/j.drugpo.2015.08.018
pubmed: 26394538
NASEN. North American Syringe Exchange Network | NASEN [Internet]. [cited 2023 Apr 10]. Available from: https://nasen.org.
Centers for Disease Control. Syringe Services Programs (SSPs) | CDC [Internet]. 2021 [cited 2023 Apr 10]. https://www.cdc.gov/ssp/index.html .
Lambdin BH, Bluthenthal RN, Tookes HE, Wenger L, Morris T, LaKosky P, et al. Buprenorphine implementation at syringe service programs following waiver of the Ryan Haight Act in the United States. Drug Alcohol Depend. 2022;237:109504.
pubmed: 35688052
pmcid: 10878423
doi: 10.1016/j.drugalcdep.2022.109504
Bachhuber MA, Thompson C, Prybylowski A, Benitez J, Mazzella S, Barclay D. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program. Substance Abuse. 2018;39(2):167–72.
pubmed: 29474119
doi: 10.1080/08897077.2018.1443541
Hood JE, Banta-Green CJ, Duchin JS, Breuner J, Dell W, Finegood B, et al. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: lessons learned from Seattle, Washington. Substance Abuse. 2020;41(3):356–64.
pubmed: 31403907
doi: 10.1080/08897077.2019.1635557
Behrends CN, Lu X, Corry GJ, LaKosky P, Prohaska SM, Glick SN, et al. Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020. Drug Alcohol Depend. 2022;232:109323.
pubmed: 35124386
pmcid: 8772135
doi: 10.1016/j.drugalcdep.2022.109323
Peirce JM, Brooner RK, Kolodner K, Schacht RL, Kidorf MS. Prospective effects of traumatic event re-exposure and post-traumatic stress disorder in syringe exchange participants. Addiction. 2013;108(1):146–53.
pubmed: 22775291
doi: 10.1111/j.1360-0443.2012.04003.x
Weathers FW, Blake DD, Schnurr PP, Kaloupek DG, Marx BP, Keane TM. The Life Events Checklist for DSM–5 (LEC-5). Washington, DC: United States Department of Veterans Affairs, National Center for PTSD; 2013.
Weathers FW, Litz BT, Keane TM, Palmieri P, Marx BP, Schnurr PP. The PTSD Checklist for DSM–5 (PCL-5). Washington, DC: United States Department of Veterans Affairs, National Center for PTSD; 2013.
Lee DJ, Weathers FW, Thompson-Hollands J, Sloan DM, Marx BP. Concordance in PTSD symptom change between DSM-5 versions of the Clinician-administered PTSD Scale (CAPS-5) and PTSD Checklist (PCL-5). Psychol Assess. 2022;34(6):604–9.
doi: 10.1037/pas0001130
pubmed: 35389681
pmcid: 9437843
Blevins CA, Weathers FW, Davis MT, Witte TK, Domino JL. The posttraumatic stress disorder checklist for DSM-5 (PCL-5): development and initial psychometric evaluation. J Trauma Stress. 2015;28(6):489–98.
pubmed: 26606250
doi: 10.1002/jts.22059
McClellan AT, Luborsky L, Woody G, O’Brien C. An Improved Diagnostic evaluation instrument for substance abuse patients: the Addiction Severity Index. J Nerv Ment Dis. 1980;168(1):26–33.
doi: 10.1097/00005053-198001000-00006
IBM Corp. IBM SPSS statistics for Windows, Version 29.0.2.0. Armonk. NY: IBM Corp; 2023.
Des Jarlais DC, McKnight C, Goldblatt C, Purchase D. Doing harm reduction better: syringe exchange in the United States. Addiction. 2009;104(9):1441–6.
pubmed: 19215605
doi: 10.1111/j.1360-0443.2008.02465.x
Kreek MJ. Extreme marginalization: addiction and other mental health disorders, stigma, and imprisonment. Ann N Y Acad Sci. 2011;1231(1):65–72.
pubmed: 21884162
pmcid: 3716375
doi: 10.1111/j.1749-6632.2011.06152.x
Richardson LA, Long C, DeBeck K, Nguyen P, Milloy MJS, Wood E, et al. Socioeconomic marginalisation in the structural production of vulnerability to violence among people who use illicit drugs. J Epidemiol Community Health. 2015;69(7):686–92.
pubmed: 25691275
doi: 10.1136/jech-2014-205079
Ti L, Richardson L, DeBeck K, Nguyen P, Montaner J, Wood E, et al. The impact of engagement in street-based income generation activities on stimulant drug use cessation among people who inject drugs. Drug Alcohol Depend. 2014;141:58–64.
pubmed: 24909853
pmcid: 4090016
doi: 10.1016/j.drugalcdep.2014.05.003
Wood E, Lloyd-Smith E, Li K, Strathdee SA, Small W, Tyndall MW, et al. Frequent needle exchange use and HIV incidence in Vancouver, Canada. Am J Med. 2007;120(2):172–9.
doi: 10.1016/j.amjmed.2006.02.030
pubmed: 17275459
Morgan-López AA, Killeen TK, Saavedra LM, Hien DA, Fitzpatrick S, Ruglass LM, et al. Crossover between diagnostic and empirical categorizations of full and subthreshold PTSD. J Affect Disord. 2020;274:832–40.
pubmed: 32664022
pmcid: 7388200
doi: 10.1016/j.jad.2020.05.031
Norman SB, Stein MB, Davidson JRT. Profiling posttraumatic functional impairment. J Nerv Ment Dis. 2007;195(1):48.
pubmed: 17220739
doi: 10.1097/01.nmd.0000252135.25114.02
Norman SB, Tate SR, Anderson KG, Brown SA. Do trauma history and PTSD symptoms influence addiction relapse context? Drug Alcohol Depend. 2007;90(1):89–96.
pubmed: 17459611
doi: 10.1016/j.drugalcdep.2007.03.002
Havens JR, Oser CB, Knudsen HK, Lofwall M, Stoops WW, Walsh SL, et al. Individual and network factors associated with non-fatal overdose among rural Appalachian drug users. Drug Alcohol Depend. 2011;115(1):107–12.
pubmed: 21126831
doi: 10.1016/j.drugalcdep.2010.11.003
Ehring T, Quack D. Emotion regulation difficulties in trauma survivors: the role of trauma type and PTSD symptom severity. Behav Ther. 2010;41(4):587–98.
doi: 10.1016/j.beth.2010.04.004
pubmed: 21035621
Tull MT, Barrett HM, McMillan ES, Roemer L. A preliminary investigation of the relationship between emotion regulation difficulties and posttraumatic stress symptoms. Behav Ther. 2007;38(3):303–13.
pubmed: 17697854
doi: 10.1016/j.beth.2006.10.001
Allen ST, Grieb SM, O’Rourke A, Yoder R, Planchet E, White RH, et al. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs. Harm Reduct J. 2019;16(1):33.
pubmed: 31109339
pmcid: 6528286
doi: 10.1186/s12954-019-0305-7
Bass JK, Annan J, McIvor Murray S, Kaysen D, Griffiths S, Cetinoglu T, et al. Controlled trial of psychotherapy for Congolese survivors of sexual violence. N Engl J Med. 2013;368(23):2182–91.
pubmed: 23738545
doi: 10.1056/NEJMoa1211853
Pearson CR, Kaysen D, Huh D, Bedard-Gilligan M. Randomized control trial of culturally adapted Cognitive Processing Therapy for PTSD substance misuse and HIV sexual risk behavior for Native American women. AIDS Behav. 2019;23(3):695–706.
doi: 10.1007/s10461-018-02382-8
pubmed: 30607757
pmcid: 6407746
Weiss WM, Murray LK, Zangana GAS, Mahmooth Z, Kaysen D, Dorsey S, et al. Community-based mental health treatments for survivors of torture and militant attacks in Southern Iraq: a randomized control trial. BMC Psychiatry. 2015;15(1):249.
pubmed: 26467303
pmcid: 4605204
doi: 10.1186/s12888-015-0622-7
Fortney JC, Bauer AM, Cerimele JM, Pyne JM, Pfeiffer PN, Heagerty P, et al. A pragmatic randomized comparative effectiveness trial of tele-integrated care and tele-referral care for treating complex psychiatric disorders in primary care. JAMA Psychiatry. 2021;78(11):1189–99.
doi: 10.1001/jamapsychiatry.2021.2318
pubmed: 34431972
Collins SE, Duncan MH, Saxon AJ, Taylor EM, Mayberry N, Merrill JO, et al. Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial. Lancet Psychiatry. 2021;8(4):287–300.
pubmed: 33713622
pmcid: 9875110
doi: 10.1016/S2215-0366(20)30489-2
Collins SE, Clifasefi SL, Nelson LA, Stanton J, Goldstein SC, Taylor EM, et al. Randomized controlled trial of harm reduction treatment for alcohol (HaRT-A) for people experiencing homelessness and alcohol use disorder. Int J Drug Policy. 2019;67:24–33.
pubmed: 30851620
pmcid: 6488431
doi: 10.1016/j.drugpo.2019.01.002
Huang LN, Flatow R, Biggs T, Afayee S, Smith K, Clark T et al. SAMHSA’s Concept of Truama and Guidance for a Trauma-Informed Approach [Internet]. Substance Abuse and Mental Health Services Administration (SAMHSA); 2014 Jul [cited 2024 Apr 23]. https://archive.hshsl.umaryland.edu/handle/10713/18559 .
Substance Abuse and Mental Health Services Administration. SAMHSA Harm Reduction Framework. Center for Substance Abuse Prevention, Substance Abuse and Mental Health Services Administration; 2023.
Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005. NSDUH Series H-57. Substance Abuse and Mental Health Services Administration: Center for Behavioral Health Statistics and Quality; 2022.
Fernández-Viña MH, Prood NE, Herpolsheimer A, Waimberg J, Burris S. State laws governing syringe services programs and participant syringe possession, 2014–2019. Public Health Rep. 2020;135(1suppl):S128–37.
doi: 10.1177/0033354920921817
Heller D, McCoy K, Cunningham C. An invisible barrier to integrating HIV primary care with harm reduction services: philosophical clashes between the harm reduction and medical models. Public Health Rep. 2004;119(1):32–9.
pubmed: 15147647
pmcid: 1502252
doi: 10.1177/003335490411900109
Mackesy-Amiti ME, Donenberg GR, Ouellet LJ. Prevalence of psychiatric disorders among young injection drug users. Drug Alcohol Depend. 2012;124(1):70–8.
pubmed: 22226707
pmcid: 3350828
doi: 10.1016/j.drugalcdep.2011.12.012
Goldstein RB, Smith SM, Chou SP, Saha TD, Jung J, Zhang H, et al. The epidemiology of DSM-5 posttraumatic stress disorder in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Soc Psychiatry Psychiatr Epidemiol. 2016;51(8):1137–48.
pubmed: 27106853
pmcid: 4980174
doi: 10.1007/s00127-016-1208-5
Ahmad F, Cisewski J, Rossen L, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics; 2023.